Quality of life of women receiving abemaciclib and endocrine therapy for breast cancer Cancer Malignant neoplasm of breast
Conditions
Interventions
Study data will be collected through three semi-structured interviews: at baseline before start of treatment, and 4 and 8 weeks later. The baseline interviews will explore patients’ understanding of t
Sponsors
University of Sussex
Eligibility
Sex/Gender
Female
Age
18 Years to 120 Years
Inclusion criteria
Inclusion criteria: 1. Diagnosis of ER+, HER2- breast cancer 2. Postmenopausal 3. Participating in the POETIC-A trial and randomised to receive abemaciclib and standard adjuvant endocrine therapy 4. Aged 18 years or over 5. Good comprehension of the English language
Exclusion criteria
Exclusion criteria: 1. Inability to understand and speak English 2. Inability to give fully informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patients’ expectations and experiences of treatment with abemaciclib and standard adjuvant endocrine therapy for early-stage high-risk breast cancer, assessed using semi-structured interviews at baseline before the start of treatment and 4 and 8 weeks later | — |
Secondary
| Measure | Time frame |
|---|---|
| Patients’ information and communication needs, assessed using semi-structured interviews at baseline before the start of treatment and 4 and 8 weeks later | — |
Countries
England, Northern Ireland, Scotland, United Kingdom, Wales
Contacts
Public ContactHelena Harder
Outcome results
None listed